A Phase 1/2 interventional study of Lenvatinib in Hepatocellular Carcinoma, sponsored by Eisai Co., Ltd.. Completed at 12 sites in 2 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-01.
Sponsored by Eisai Co., Ltd. · Phase 1/2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 36th largest by enrollment, is the only one that started in 2009, is one of 9 in phase 1/2, and was the 1st registered.
3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.
Browse Carcinoma, Hepatocellular studies →57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 19–79
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 79 · Phase 3 17 · Phase 4 5
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 53 across 2,621 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 48 across the 121 interventional studies. Of the 21 that completed or were terminated, 6 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 121 have an industry lead sponsor. The 10 most frequent:
Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd.: none open now, 4 under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 1/2, and was the 2nd registered.
Eisai Co., Ltd.’s Carcinoma, Hepatocellular studies by the year they started, since 2004.
14 of the studies testing lenvatinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041477Phase 3Sun Yat-sen UniversityConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | 2027-07 |
| NCT05621499Tianjin Medical University Cancer Institute and HospitalHAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | 2026-11 |
| NCT07081633AstraZenecaDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | 2026-11-30 |
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT06524466Sun Yat-sen UniversityNeoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | 2026-12-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, from their registry updates:
Among Eisai Co., Ltd.’s 20 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is administered continually once daily in participants with advanced hepatocellular carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lenvatinib
In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
Also known as: E7080
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib
The MTD was defined as the highest dose level at which no more than 1 of 6 participants had a dose limiting toxicities (DLT). DLT was defined as any of the following events: grade 4 or higher hematologic toxicity or grade 3 thrombocytopenia that required blood transfusion, grade 3 or higher nonhematologic toxicity, grade 4 hypertension uncontrolled by antihypertensive drug(s), aspartate aminotransferase/alanine aminotransferase (AST/ALT) greater than (\>) 10.0\*upper limit of normal (ULN), proteinuria 4+ by urine dipstick, proteinuria 3+ by urine dipstick was to be monitored by 24-hour urine collection, proteinuria \>3.5 gram (g) for 24 hours, diarrhea/vomiting/nausea of grade 3 or higher that was uncontrollable despite maximal supportive therapies and abnormal clinical laboratory values that required no treatment, grade 3 proteinuria by dipstick, diarrhea/vomiting/nausea that was managed with supportive therapies were not considered as DLT.
Time frame: Up to 28 days (Cycle1)
Phase 2: Time to Progression (TTP) by Independent Review Assessment
TTP was defined as the time from the date of registration to the date when progressive disease (PD) was first confirmed. PD was evaluated according to modified response evaluation criteria in solid tumors (mRECIST) by an independent imaging review. PD was defined as at least a 20 percent (%) increase in the sum of long diameter (LD) of target lesions as compared with the smallest sum of LD and the increase of LD was at least 5 millimeter (mm) (including new lesions).
Time frame: From day of registration to the day when PD was first confirmed (approximately up to 6.1 years)
Phase 1: Best Overall Response (BOR) of Lenvatinib by Investigator Assessment
BOR was performed using RECIST1.1 and was measured as complete response (CR) defined as when an overall response of CR was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of CR was confirmed and the BOR established as CR was regarded as the "CR confirmed date), partial response (PR) defined as when the overall response of PR or better (CR or PR) was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of PR was confirmed and the BOR established as PR will be regarded as the "PR confirmed date), PD defined as when the BOR was neither CR, PR, or stable disease (SD), and the overall response was PD, SD defined as when the BOR obtained was neither CR nor PR, but no PD from the initial administration to the end of Cycle 2 and the overall response of SD or better occurred at least once and not evaluable (NE) was when the overall response was NE in all cases.
Time frame: Every 8 weeks (approximately up to 18.4 months)
Phase 1: Objective Response Rate (ORR) by Investigator Assessment
ORR was defined as the percentage of participants who achieved a tumor response measured by RECIST 1.1 of CR defined as disappearance of all target lesions (a short diameter is less than (\<)10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
Time frame: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Phase 1: Disease Control Rate (DCR) by Investigator Assessment
DCR was measured by RECIST 1.1 and defined as CR which was defined as disappearance of all target lesions (a short diameter was \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.
Time frame: Up to Week 16
Phase 2: Progression-free Survival (PFS) by Independent Review Assessment
PFS was defined as the time from the date of registration until the date when PD was first confirmed or death (whichever occurred first) as determined by mRECIST and PD was defined as at least a 20% increase in the sum of long diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.
Time frame: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Phase 2: Objective Response Rate (ORR) by Independent Review Assessment
ORR was defined as the percentage of participants who achieved a tumor response measured by mRECIST of CR defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
Time frame: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Phase 2: Disease Control Rate (DCR) by Independent Review Assessment
DCR was measured by mRECIST and defined as CR which was defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.
Time frame: Weeks 8 and 16
Phase 2: Overall Survival (OS)
OS was defined as the time from the date of registration until the date of death.
Time frame: From day of registration to the day of death (approximately 6.1 years)
Participants took part in the study at 12 sites in Japan and 2 sites in South Korea from 24 Jul 2009 to 13 Aug 2015.
| Milestone | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg |
|---|---|---|---|---|---|
| Started | 6 | 3 | 6 | 5 | 0 |
| Completed | 6 | 3 | 6 | 5 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 46 |
| Completed | 0 | 0 | 0 | 0 | 33 |
| Not completed | 0 | 0 | 0 | 0 | 13 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Need more reduction of dose | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: 14 days washout for recovery due to ae | 0 | 0 | 0 | 0 | 4 |
The MTD was defined as the highest dose level at which no more than 1 of 6 participants had a dose limiting toxicities (DLT). DLT was defined as any of the following events: grade 4 or higher hematologic toxicity or grade 3 thrombocytopenia that required blood transfusion, grade 3 or higher nonhematologic toxicity, grade 4 hypertension uncontrolled by antihypertensive drug(s), aspartate aminotransferase/alanine aminotransferase (AST/ALT) greater than (\>) 10.0\*upper limit of normal (ULN), proteinuria 4+ by urine dipstick, proteinuria 3+ by urine dipstick was to be monitored by 24-hour urine collection, proteinuria \>3.5 gram (g) for 24 hours, diarrhea/vomiting/nausea of grade 3 or higher that was uncontrollable despite maximal supportive therapies and abnormal clinical laboratory values that required no treatment, grade 3 proteinuria by dipstick, diarrhea/vomiting/nausea that was managed with supportive therapies were not considered as DLT.
| milligram (mg) | Phase 1: Group 1: Levatinib 12 or 16 mg (CP Score 5 or 6) | Phase 1: Group 2: Lenvatinib 8 or 12 mg (CP Score 7 or 8) |
|---|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib | 12 | 8 |
TTP was defined as the time from the date of registration to the date when progressive disease (PD) was first confirmed. PD was evaluated according to modified response evaluation criteria in solid tumors (mRECIST) by an independent imaging review. PD was defined as at least a 20 percent (%) increase in the sum of long diameter (LD) of target lesions as compared with the smallest sum of LD and the increase of LD was at least 5 millimeter (mm) (including new lesions).
| months | Phase 2 : Lenvatinib :12 mg |
|---|---|
| Phase 2: Time to Progression (TTP) by Independent Review Assessment | 7.40 (5.50 to 9.40) |
BOR was performed using RECIST1.1 and was measured as complete response (CR) defined as when an overall response of CR was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of CR was confirmed and the BOR established as CR was regarded as the "CR confirmed date), partial response (PR) defined as when the overall response of PR or better (CR or PR) was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of PR was confirmed and the BOR established as PR will be regarded as the "PR confirmed date), PD defined as when the BOR was neither CR, PR, or stable disease (SD), and the overall response was PD, SD defined as when the BOR obtained was neither CR nor PR, but no PD from the initial administration to the end of Cycle 2 and the overall response of SD or better occurred at least once and not evaluable (NE) was when the overall response was NE in all cases.
| Participants | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg |
|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 |
| Partial Response | 1 | 1 | 1 | 0 |
| Stable Disease | 2 | 2 | 4 | 2 |
| Progressive Disease | 2 | 0 | 1 | 3 |
| Not Evaluable | 1 | 0 | 0 | 0 |
ORR was defined as the percentage of participants who achieved a tumor response measured by RECIST 1.1 of CR defined as disappearance of all target lesions (a short diameter is less than (\<)10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
| percentage of participants | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg |
|---|---|---|---|---|
| Phase 1: Objective Response Rate (ORR) by Investigator Assessment | 16.7 | 33.3 | 16.7 | 0 |
DCR was measured by RECIST 1.1 and defined as CR which was defined as disappearance of all target lesions (a short diameter was \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.
| percentage of participants | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg |
|---|---|---|---|---|
| Phase 1: Disease Control Rate (DCR) by Investigator Assessment | 50 | 100 | 83.3 | 40.0 |
PFS was defined as the time from the date of registration until the date when PD was first confirmed or death (whichever occurred first) as determined by mRECIST and PD was defined as at least a 20% increase in the sum of long diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.
| months | Phase 2 : Lenvatinib :12 mg |
|---|---|
| Phase 2: Progression-free Survival (PFS) by Independent Review Assessment | 7.40 (5.50 to 9.40) |
ORR was defined as the percentage of participants who achieved a tumor response measured by mRECIST of CR defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
| percentage of participants | Phase 2 : Lenvatinib :12 mg |
|---|---|
| Phase 2: Objective Response Rate (ORR) by Independent Review Assessment | 41.5 (26.3 to 57.9) |
DCR was measured by mRECIST and defined as CR which was defined as disappearance of all target lesions (a short diameter is \<10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.
| percentage of participant | Phase 2 : Lenvatinib :12 mg |
|---|---|
| Week 8 | 87.8 (73.8 to 95.9) |
| Week 16 | 78.0 (62.4 to 89.4) |
OS was defined as the time from the date of registration until the date of death.
| months | Phase 2 : Lenvatinib :12 mg |
|---|---|
| Phase 2: Overall Survival (OS) | 18.30 (12.70 to 25.10) |
Collected over From start of study drug administration until approximately up to 6.1 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Group 1: Lenvatinib: 12 mg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1: Group 1: Lenvatinib: 16 mg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1: Group 2: Lenvatinib: 8 mg | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Phase 1: Group 2: Lenvatinib: 12 mg | 1/5 (20%) | 3/5 (60%) | 5/5 (100%) |
| Phase 2: Lenvatinib: 12 mg | 32/46 (69.6%) | 22/46 (47.8%) | 46/46 (100%) |
| Event | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/6 | 1/3 | 0/6 | 0/5 | 1/46 |
| Hepatic encephalopathyNervous system disorders | 0/6 | 1/3 | 0/6 | 1/5 | 5/46 |
| Hepatic failureHepatobiliary disorders | 0/6 | 0/3 | 0/6 | 1/5 | 0/46 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/3 | 1/6 | 1/5 | 0/46 |
| HaematemesisGastrointestinal disorders | 0/6 | 0/3 | 1/6 | 0/5 | 0/46 |
| HyperbilirubinaemiaHepatobiliary disorders | 1/6 | 0/3 | 1/6 | 0/5 | 0/46 |
| Biliary tract infectionInfections and infestations | 1/6 | 0/3 | 0/6 | 0/5 | 0/46 |
| Renal impairmentRenal and urinary disorders | 0/6 | 0/3 | 0/6 | 0/5 | 3/46 |
| Oedema peripheralGeneral disorders | 0/6 | 0/3 | 0/6 | 0/5 | 2/46 |
| Acute coronary syndromeCardiac disorders | 0/6 | 0/3 | 0/6 | 0/5 | 1/46 |
| Event | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/6 | 3/3 | 0/6 | 0/5 | 19/46 |
| DiarrhoeaGastrointestinal disorders | 6/6 | 3/3 | 6/6 | 3/5 | 20/46 |
| NauseaGastrointestinal disorders | 2/6 | 3/3 | 3/6 | 4/5 | 16/46 |
| FatigueGeneral disorders | 5/6 | 3/3 | 5/6 | 5/5 | 25/46 |
| Decreased appetiteMetabolism and nutrition disorders | 6/6 | 2/3 | 3/6 | 5/5 | 28/46 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 5/6 | 3/3 | 3/6 | 2/5 | 30/46 |
| HypertensionVascular disorders | 5/6 | 3/3 | 3/6 | 4/5 | 35/46 |
| VomitingGastrointestinal disorders | 3/6 | 3/3 | 2/6 | 2/5 | 11/46 |
| Oedema peripheralGeneral disorders | 0/6 | 2/3 | 5/6 | 1/5 | 16/46 |
| Blood thyroid stimulating hormone increasedInvestigations | 5/6 | 1/3 | 2/6 | 1/5 | 12/46 |
All participants who received at least 1 dose of lenvatinib, and had at least 1 post baseline efficacy evaluation.
| Age, Customized(Participants) | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg | Total |
|---|---|---|---|---|---|---|
| >=37 years and <=80 years | 6 | 3 | 6 | 5 | 46 | 66 |
| Sex: Female, Male(Participants) | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 2 | 0 | 0 | 13 | 16 |
| Male | 5 | 1 | 6 | 5 | 33 | 50 |
| Race (NIH/OMB)(Participants) | Phase 1: Group 1: Lenvatinib: 12 mg | Phase 1: Group 1: Lenvatinib: 16 mg | Phase 1: Group 2: Lenvatinib: 8 mg | Phase 1: Group 2: Lenvatinib: 12 mg | Phase 2: Lenvatinib: 12 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 3 | 6 | 5 | 46 | 66 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Jul 2009 to primary completion in Jun 2014, 58 months.
Results were first posted in Feb 2019, 4 years 7 months after primary completion.
Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 58 months is above that.
Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib